The “Neurodegenerative Disease Market” report 2019 delivers up-to-date information about market changes and prospective threats, as well as in-depth knowledge of products and services, which can help in planning and in executing category management activities. Moreover, it focuses on the cost-saving aspects of procurement and on providing insights that can lead to optimization of category spend.
Get a Sample Copy of the Report At – https://www.industryresearch.co/enquiry/request-sample/14244853
Top Key Players of Neurodegenerative Disease Market Are:
Reasons to buy:
- In-depth analysis of the market on the global and regional level.
- Major changes in market dynamics and competitive landscape.
- Segmentation on the basis of type, application, geography and others.
- Historical and future market research in terms of size, share, growth, volume & sales.
- Major changes and assessment in market dynamics & developments.
- Industry size & share analysis with industry growth and trends.
- Emerging key segments and regions
- Key business strategies by major market players and their key methods.
- The research report covers size, share, trends and growth analysis of the Neurodegenerative Disease Market on the global and regional level.
Inquire or Share Your Questions If Any Before the Purchasing This Report – https://www.industryresearch.co/enquiry/pre-order-enquiry/14244853
Scope of the Report:
Neurodegenerative Disease market covers the outlook for overall market status, size and share. The report provides complete coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Neurodegenerative Disease market report also presents the market competition landscape and a corresponding detailed analysis of the major vendor in the market.
Key Market Trends:
Parkinson’s Disease Segment by Indication Type is Expected to Be the Fastest Growing Segment
The initial symptoms of Parkinson’s disease include shaking, rigidity, uneasiness in walking, and slowness. Anxiety and depression are very common in patients suffering from Parkinson’s disease. Anti-Parkinson drugs, such as Levodopa and Carbidopa, are the most commonly administered drugs, along with dopamine agonists. Ropinirole, Pramipexole, and Rotigotine are some common dopamine agonists prescribed for the disease. Selegiline and Rasagiline are the drugs that conserve dopamine and prevent degradation. COMT inhibitors are also administered to prevent the degradation of dopamine. According to the Parkinson’s Disease Foundation, nearly 10 million people worldwide are living with Parkinson’s disease. The risk of Parkinson’s disease increases with age. The growing aging population, especially in North America and Europe, is the primary factor propelling the growth of the market. The increasing awareness and incidences of the disease are boosting the market growth. According to the Parkinson’s Disease Foundation, medication cost for a patient with the disease is on an average USD 2,500 a year, and therapeutic surgery costs nearly USD 100,000 per person. In 2017, North America accounted for the largest market, followed by Europe and Asia-Pacific.
North America is Expected to Dominate the Market
North America is the most significant region in Parkinson’s drugs market. As many as one million Americans live with Parkinson’s disease (PD), which is more than the combined number of people diagnosed with multiple sclerosis, muscular dystrophy, and Lou Gehrig’s disease. According to Parkinson’s news, 2018, approximately 1.2 million people in the United States are predicted to have Parkinson’s disease by 2030. It is the second-most common neurodegenerative disorder in the United States. Also, there are thousands of patients who go undetected. As the US population continues to age, the number of people living with Parkinson disease (PD) continues to grow, and it is expected to double between 2010 and 2040. Recently, the Food and Drug Administration (FDA) approved safinamide (Xadago) tablets as an add-on treatment to levodopa/carbidopa for patients with PD, who are experiencing “off” episodes. FDA approved the drug in March 2017. On the other hand, patients are adopting the generics due to the low cost, and are further expected to restrain the patented drugs. Hence, this generic competition between the new entrants is expected to show a steady growth rate, during the forecast period.
Neurodegenerative Disease Market Report contents include:
– Analysis of the Neurodegenerative Disease market including revenues, future growth, market outlook
– Historical data and forecast
– Regional analysis including growth estimates
– Analyzes the end user markets including growth estimates.
– Profiles on Neurodegenerative Disease including products, sales/revenues, and market position
– Market structure, market drivers and restraints.
Purchase this Report (Price 4250 USD for a Single-User License) – https://www.industryresearch.co/purchase/14244853
Detailed TOC of Neurodegenerative Disease Market Report Are:
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Neurological Disorders
4.2.2 Increasing Public Awareness
4.2.3 Strong Product Pipeline for Neurodegenerative Disease Treatment
4.3 Market Restraints
4.3.1 Patent Expiry of Neurodegenerative Disease Treatment Products
4.3.2 Stringent Regulatory Guidelines
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Indication Type
5.1.1 Parkinson’s Disease
5.1.2 Amyotrophic Lateral Sclerosis
5.1.3 Alzheimer’s Disease
5.1.4 Huntington Disease
5.1.5 Other Indication Types
5.2 By Drug Type
5.2.1 N-methyl-D-aspartate Receptor
5.2.2 Selective Serotonin Reuptake Inhibitor
5.2.3 Dopamine Inhibitors
5.2.4 Other Drug Types
5.3.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.3.4 Middle East & Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle East & Africa
5.3.5 South America
220.127.116.11 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Amneal Pharmaceuticals Inc.
6.1.3 Boehringer Ingelheim International GmbH
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 GlaxoSmithKline PLC
6.1.6 Merck & Co. Inc.
6.1.7 Pfizer Inc.
6.1.8 Teva Pharmaceutical
6.1.9 UCB SA
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Name: Ajay More
Phone: US +14242530807/ UK +44 20 3239 8187
Email: [email protected]
Our Other Reports: